Work

A Phase I Open-Label Study to Evaluate the Safety and Tolerability of Medi4736, an Anti-Programmed Cell Death-Ligand 1(Pd-L1) Antibody, in Combination with Tremelimumab in Patients with Advanced Non-Small Cell Lung Cancer (Nsclc)

Year: 2014

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdu349.106

Authors: S.J. Antonia, S. Goldberg, A. Balmanoukian, R. Narwal, P.B. Robbins, G. D'Angelo, A. Blake-Haskins, J.J. Karakunnel, N. Rizvi

Institutions: Moffitt Cancer Center, Yale University, Angeles Clinic and Research Institute, Memorial Sloan Kettering Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2294542576

FWCI: 0.819

Cites:

Cited by: 5

Related to: 10